Gavin Hirst

Gavin Hirst is a seasoned expert in medicinal chemistry and drug discovery, currently serving as a Board of Directors Advisor at Zafrens and an Advisory Board Member at Intelligence Ventures. Gavin Hirst operates Gavin Hirst Enterprises LLC, providing consulting services in drug discovery and medicinal chemistry since April 2015. Previously, Gavin Hirst held key leadership roles including Chief Scientific Officer at Atomwise, SVP Medicinal Chemistry and Interim CSO at Turning Point Therapeutics, and Global Head Integrated Drug Discovery at Eurofins Discovery. Gavin Hirst's early career involved significant contributions at The Janssen Pharmaceutical Companies, Takeda California, Mpex Pharmaceuticals, and SGX Pharmaceuticals, where achievements include the co-invention of the FDA-approved Vaborbactam. Gavin Hirst earned a Ph.D. in Organic Chemistry from UC Irvine and a B.Sc. in Chemistry from the University of Bradford.